Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Spriggs

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|October 29, 2011
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group studyGinger J Gardner, Raymond E Baser, Mark F Brady, et al.
Gynecologic Oncology|October 20, 2009
Consolidation strategies in ovarian cancer: observations for future clinical trialsPaul Sabbatini, David Spriggs, Carol Aghajanian, et al.
Stroke|April 1, 2006
Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapyJennifer Somerfield, P Alan Barber, Neil E Anderson, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Clinical Medicine (London, England)|May 17, 2012
Simple prescribing errors and allergy documentation in medical hospital admissions in Australia and New ZealandLorna Barton, Judith Futtermenger, Yash Gaddi, et al.
Journal for Immunotherapy of Cancer|August 26, 2021
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancerChrisann Kyi, Ekaterina Doubrovina, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II TrialPaul Sabbatini, Carol Aghajanian, Mario Leitao, et al.
Cancer Immunology Research|April 30, 2014
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trialTakemasa Tsuji, Paul Sabbatini, Achim A Jungbluth, et al.
Geriatrics & Gerontology International|March 28, 2012
Prevalence of resuscitation orders among residents from aged care facilities admitted to general medical unitsJordan Y Z Li, Tuck Y Yong, Diana McNeill, et al.
Cancer|February 6, 2009
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group studyChunqiao Tian, Maurie Markman, Richard Zaino, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|October 29, 2011
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group studyGinger J Gardner, Raymond E Baser, Mark F Brady, et al.
Gynecologic Oncology|October 20, 2009
Consolidation strategies in ovarian cancer: observations for future clinical trialsPaul Sabbatini, David Spriggs, Carol Aghajanian, et al.
Stroke|April 1, 2006
Not all patients with atrial fibrillation-associated ischemic stroke can be started on anticoagulant therapyJennifer Somerfield, P Alan Barber, Neil E Anderson, et al.
Gynecologic Oncology|July 7, 2007
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trialsMichelle L Harrison, Martin E Gore, David Spriggs, et al.
Clinical Medicine (London, England)|May 17, 2012
Simple prescribing errors and allergy documentation in medical hospital admissions in Australia and New ZealandLorna Barton, Judith Futtermenger, Yash Gaddi, et al.
Journal for Immunotherapy of Cancer|August 26, 2021
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancerChrisann Kyi, Ekaterina Doubrovina, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II TrialPaul Sabbatini, Carol Aghajanian, Mario Leitao, et al.
Cancer Immunology Research|April 30, 2014
Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trialTakemasa Tsuji, Paul Sabbatini, Achim A Jungbluth, et al.
Geriatrics & Gerontology International|March 28, 2012
Prevalence of resuscitation orders among residents from aged care facilities admitted to general medical unitsJordan Y Z Li, Tuck Y Yong, Diana McNeill, et al.
Cancer|February 6, 2009
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group studyChunqiao Tian, Maurie Markman, Richard Zaino, et al.
Pageof 5